A simple diagnostic index comprising epithelial membrane antigen and fibronectin for hepatocellular carcinoma

Attallah, Abdelfattah M.; El‐Far, Mohamed; Malak, Camelia A. Abdel; Omran, Mohamed M.; Kosari, Farid; Yahya, Raida S.; Saad, Entsar A.; Albannan, Mohamed S.; Attallah, Ahmed A.; Basuni, Mohamed A. El; Ali, Islam S.; Abed, Safaa B.; Naggar, M A El

doi:10.5604/16652681.1171774

Cited by 25 publications

(14 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the current study, significant increase in serum AST and ALT activity was recorded in all diseased groups compared to control. HCC showed elevated AST compared to liver cirrhosis in consistence with other reports and as explained previously cancer tissue seems to release AST into circulation at a faster rate than non-cancerous parenchyma (Attallah et al, 2015). Clinical utilization of AST/ALT ratio is more than utilization of individual elevated levels (Parkes et al, 2006;Saad, 2014).…”

Section: Discussionsupporting

confidence: 74%

“…Liver cirrhosis is a common recognized threat for primary hepatic malignancy, 7% of cirrhotic people develop HCC, and raises the threat for extra hepatic cancers development (Bridgewater et al, 2014;Saad et al, 2017a). The efficacy in monitoring cancer patients may get better via utilizing the proper single or group of markers (Attallah et al, 2015). Therefore, our aim was to correlate CD133 and CK19 with DNA cell cycle in chronic HCV (genotype-4) patients with hepatic or extra hepatic cancer as a starting step for the study of their combination as diagnostic tool in those patients.…”

Section: Discussionmentioning

confidence: 99%

“…Among these, chronic HCV is the chief cause of liver fibrosis, liver cirrhosis and liver cancer and, in fact, it is one of the major five causes lead to death (Saad, 2014;El-Emshaty et al, 2014;Saad et al, 2017a). Patients with cirrhosis have the highest threat of developing HCC and may be at hazard for extra hepatic cancer (Attallah et al, 2015;Bridgewater et al, 2014).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Associations between CD133, CK19 and G2/M in cirrhotic HCV (genotype-4) patients with or without accompanying tumor

El-Emshaty¹,

Saad²,

Gouida³

et al. 2018

Biocell

View full text Add to dashboard Cite

Hepatitis C virus (HCV)-cirrhotic patients have the highest threat of developing hepatocellular carcinoma (HCC) and may be at risk of extra hepatic cancer. The present study was designed to investigate CD133 and CK19 in HCV (genotype-4)-cirrhotic patients with/without HCC or extra hepatic cancer, to assess the degree of their correlation with cell cycle abnormalities and finally to assess the role of their combination as diagnostic tool for discrimination of cirrhotic patients with HCC from those with extra hepatic cancer. The study included 77 HCV-cirrhotic patients and 20 healthy non-disease control group. Patients were categorized histo-pathologically into: 24 have only liver cirrhosis, 26 with HCC, and 27 patients with extra hepatic cancer. Cell cycle abnormalities, CD133 and CK19 were determined by flow cytometry technique. CD133 and CK19 showed marked elevation in HCC and extra hepatic cancer compared with liver cirrhosis and control subjects (p<0.0001). Positive associations were noted between CK19, CD133 and G2/M. They were gradually increased with progression from liver cirrhosis to HCC. Combination of the three showed the best AUC (0.978) and accuracy (92.5%) for discrimination of HCC from extra hepatic cancer. Combined CD133 with G2/M and CK19 comprises an excellent diagnostic panel for discrimination of HCV-cirrhotic patients with HCC from those with extra hepatic cancer.

show abstract

Section: Discussionsupporting

confidence: 74%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Associations between CD133, CK19 and G2/M in cirrhotic HCV (genotype-4) patients with or without accompanying tumor

El-Emshaty¹,

Saad²,

Gouida³

et al. 2018

Biocell

View full text Add to dashboard Cite

show abstract

“…More interestingly, this triple combination could differentiate HCC from liver fibrosis with an AUC of 0.94 with 80% sensitivity and 92% specificity [54] . Epithelial membrane antigen and fibronectin, of which the serum levels were increased in HCC, when in conjunction with total bilirubin and APF, could identify HCC from cirrhosis with an AUC of 0.92 with 89% sensitivity and 85% specificity [55] . Combined use of plasma protein with immune cells in HCC diagnosis has been published as well.…”

Section: Biomarker Combinations For Hcc Diagnosismentioning

confidence: 99%

Molecular diagnosis of hepatocellular carcinoma: trends in biomarkers combination to enhance early cancer detection

Chia¹,

Wong²,

Luk³

2019

View full text Add to dashboard Cite

Despite of the advances in clinical imaging and applied research in proteomic biomarkers, liver cancer, especially hepatocellular carcinoma remains detected at the very late and advanced stages when curable treatments are unavailable and ineffective. In this regard, there are still huge unmet medical needs in developing and clinically validating those highpotential protein biomarkers preferably in liquid biopsy samples. This review provides a glimpse of emerging biomarkers together with detection tools and techniques which are potentially commercially available to the markets. We also discuss several diagnostic biomarkers having therapeutic potential for developing first-in-class medicines.

show abstract

“…These markers are secreted by the liver cells and elevated in hepatic brosis [10][11][12][13][14]. DCS is the most powerful antigen-presenting cell and HCV infection altered many DCs functions.…”

Section: Introductionmentioning

confidence: 99%

CD86/Programmed Death-Ligand-1 as a Predictor Ratio for Response to Directly Acting Antiviral Therapy of Chronic Hepatitis in Egyptian Patients

Attallah

Omran

Askary

et al. 2022

Preprint

View full text Add to dashboard Cite

Objectives:Predictors of direct-acting antivirals response of HCV serve as assessment methods and help to treat doctors identify patients who are likely or unlikely to SVR. Methods:Egyptian chronic hepatitis C patients (N=300) were divided into 2 groups with 150 patients each. Group 1: received triple therapy (Sofosbuvir, Pegylated interferon, and ribavirin) for 12 weeks. Group 2: received dual therapy (Sofosbuvir and ribavirin) for 24 weeks. For all patients, routine blood markers, extracellular matrix markers, and dendritic cell markers were done. Hyaluronic acid, Collagen IV, Procollagen III peptide, laminin, platelet-derived growth factor and tissue inhibitor of metalloproteinase-1, were all performed using ELISA. Dendritic cells Co-stimulatory markers (CD40, CD83, and CD86), and co-inhibitory marker (PD-L1) were evaluated by real-time PCR.Results: SVR is associated with a decrease in the extracellular matrix markers and dendritic cell markers. AST/ALT (p= 0.003), Fibroscan (p= 0.024), CDs co-stimulatory markers and PD-L1 (p= 0.05-p< 0.0001) were differentiated between responders and non-responders. Using multivariate analysis exhibited that the decrease in PDL1 levels was significant (p=0.012) and increase significant (p= 0.024) in CD86 associated with SVR. CD 86/ PDL-1 ratio had an AUC of 0.82 for prediction SVR. Conclusions:Baseline CD 86/ PDL-1 ratio was the only marker predicting SVR.

show abstract

A simple diagnostic index comprising epithelial membrane antigen and fibronectin for hepatocellular carcinoma

Abstract: A four-marker index may improve the early detection of HCC with a high degree of accuracy.

Cited by 25 publications

References 46 publications

Associations between CD133, CK19 and G2/M in cirrhotic HCV (genotype-4) patients with or without accompanying tumor

Associations between CD133, CK19 and G2/M in cirrhotic HCV (genotype-4) patients with or without accompanying tumor

Molecular diagnosis of hepatocellular carcinoma: trends in biomarkers combination to enhance early cancer detection

CD86/Programmed Death-Ligand-1 as a Predictor Ratio for Response to Directly Acting Antiviral Therapy of Chronic Hepatitis in Egyptian Patients

Contact Info

Product

Resources

About